Gerberding received her undergraduate and MD degrees from Case Western Reserve University and a Master of Public Health from the University of California, Berkeley. She is also an elected member of the National Academy of Medicine. She serves on the Boards of Cerner Corporation and MSD Wellcome Trust Hilleman Laboratories and co-chairs the CSIS Commission on Strengthening America’s Health Security. Gerberding was Director of the United States CDC, where she led the agency through SARS and over 40 emergency responses to public health crises. Formerly, she was President of Vaccines at Merck and subsequently oversaw global public policy and strategic communications for the company. Julie Gerberding is Chief Patient Officer and Executive Vice President, Population Health & Sustainability at Merck. “We are deeply grateful to our late co-founder, Tachi Yamada, MD, who brought together this talented and passionate group to address a major unmet need in global health and to help grow HilleVax into a leading global vaccines company.”ĭr. “We are extremely pleased to welcome to the HilleVax board such a distinguished group of biopharmaceutical and global health executives with extensive experience in vaccines, clinical and commercial development, and capital formation,” further commented Dr. Formerly, Director of Vaccine Delivery at the Bill & Melinda Gates Foundation and Special Assistant to the President for Biodefense at the White House. President of the Global Vaccine Business Unit at Takeda. Formerly Global President of Emerging Markets at Pfizer and Global President of Pfizer Vaccines. Formerly, Director of the National Institutes of Health of Mexico. Executive Director of the University of California San Francisco (UCSF) Institute for Global Health Sciences. Formerly, Chief Financial Officer of several public life sciences companies. Chair of the Board of Omada Health and director and audit chair of public and private life sciences companies. Formerly, President of Merck Vaccines and Director of the U.S. Executive Vice President and Chief Patient Officer of Merck. HilleVax has also appointed five additional members to the board of directors, including: In connection with the financing, Patrick Heron, Managing Partner at Frazier, Elise Wang, Partner at Deerfield, and Shelley Chu, MD, PhD, Partner at Lightspeed, have joined the company’s board of directors. ![]() “We welcome their support in our efforts to advance HIL-214, which we believe has the potential to be the first-ever vaccine approved for norovirus infections.” ![]() “We are delighted with the quality of the investor group participating in this oversubscribed crossover financing,” said Rob Hershberg, MD, PhD, Chairman and Chief Executive Officer of HilleVax. The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, today announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Franklin Templeton, Catalys Pacific, Samsara BioCapital, BVF Partners LP, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |